Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Operating Leases (2019 - 2025)

Myriad Genetics (MYGN) has disclosed Operating Leases for 7 consecutive years, with $83.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 5.57% to $83.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $83.0 million, a 5.57% decrease, with the full-year FY2025 number at $83.0 million, down 5.57% from a year prior.
  • Operating Leases was $83.0 million for Q4 2025 at Myriad Genetics, down from $84.9 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $130.9 million in Q4 2022 to a low of $5.9 million in Q1 2023.
  • A 5-year average of $76.6 million and a median of $85.6 million in 2025 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: crashed 95.21% in 2023, then skyrocketed 1498.31% in 2024.
  • Myriad Genetics' Operating Leases stood at $79.3 million in 2021, then soared by 65.07% to $130.9 million in 2022, then fell by 25.59% to $97.4 million in 2023, then dropped by 9.75% to $87.9 million in 2024, then decreased by 5.57% to $83.0 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Operating Leases are $83.0 million (Q4 2025), $84.9 million (Q3 2025), and $86.2 million (Q2 2025).